Santhera Pharmaceuticals has signed an exclusive distribution agreement with Clinigen Group for the supply and distribution of AGAMREE for the treatment of Duchenne muscular dystrophy (DMD).
The novel agreement will see Clinigen take responsibility for the distribution of AGAMREE in countries where it is currently unavailable through Santhera or its associated distribution partners.
Patients will have access to AGAMREE on a case-by-case basis, as the steroid-based treatment should be administered when there is no suitable alternative.
Under the terms of the agreement, Santhera will receive the majority share of revenue generated from the extension of AGAMREE's global supply.
Currently, the therapeutic has been commercialised in Germany and Austria, while Santhera plans to launch the treatment in other major European markets such as the UK in early 2025.
The company also has plans to introduce AGAMREE to the French, Spanish and Italian markets as 2025 progresses.
Chief Commercial Officer of Santhera, Geert Jan van Daal, commented: “This distribution agreement with Clinigen, which is complementary to other, earlier announced, partnerships and agreements, will allow Santhera to significantly increase our service level to patients and healthcare professionals through processing individual requests for AGAMREE from geographies in which Santhera is not directly represented or while negotiations with local partners are ongoing,”
“DMD is one of the most common and devastating types of muscular degeneration," stated Senior VP of Europe and Partner Markets at Clinigen, Julie Gosper.
"It is a progressive condition diagnosed in childhood and it is encouraging to be able to help healthcare professionals support appropriate patients with an additional treatment option. We look forward to working with Santhera to make AGAMREE available to patients globally on an unlicensed basis in those territories where it is not currently licensed or reimbursed. This partnership demonstrates our ongoing commitment to accelerate access to medicines, to improve the quality of people’s lives around the world,”